BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30216522)

  • 1. Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis.
    Chen L; Hsi AC; Kothari A; Dehner LP; Hayashi RJ; Coughlin CC
    Pediatr Dermatol; 2018 Nov; 35(6):e402-e403. PubMed ID: 30216522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
    Hui Ong EL; Sinha R; Jmor S; Fearfield L
    Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of vemurafenib-induced keratosis pilaris-like eruption.
    Wang CM; Fleming KF; Hsu S
    Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
    Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
    J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
    Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
    J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 8. Vemurafenib-induced eccrine squamous syringometaplasia.
    Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
    Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
    Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
    Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.
    Gandolfi L; Adamo S; Pileri A; Broccoli A; Argnani L; Zinzani PL
    J Natl Compr Canc Netw; 2015 Jun; 13(6):715-8. PubMed ID: 26085387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
    Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
    Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
    Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful drug desensitization after vemurafenib-induced rash].
    Klossowski N; Kislat A; Homey B; Gerber PA; Meller S
    Hautarzt; 2015 Apr; 66(4):221-3. PubMed ID: 25698338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib-induced pityriasis amiantacea: a case report.
    Bilgiç Ö
    Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
    Charles J; Beani JC; Fiandrino G; Busser B
    J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
    [No Abstract]   [Full Text] [Related]  

  • 19. Perianal presentation of Langerhans cell histiocytosis in children.
    Tinsa F; Brini I; Kharfi M; Mrad K; Boussetta K; Bousnina S
    Gastroenterol Clin Biol; 2010 Jan; 34(1):95-7. PubMed ID: 19864102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.